Skip to content

Mechanical Heat Recovery Ventilation on House Dust Mite Sensitive Asthma

Randomised Controlled Trial of Mechanical Heat Recovery Ventilation on Asthma Control of Patients Allergic to the House Dust Mite

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00148096
Enrollment
119
Registered
2005-09-07
Start date
2003-02-28
Completion date
2007-04-30
Last updated
2009-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

asthma, house dust mite, allergy, housing, avoidance, humidity

Brief summary

Asthma has become increasingly common in the UK, demanding our consideration of the cause. Many patients with asthma are allergic to house dust mites, which thrive in modern housing. Improving ventilation in the home has been shown to reduce dust mite levels, by reducing humidity levels. It is hoped that, by removing the dust mites from homes, asthma may improve. In this study, 140 volunteers will have their carpets steam-cleaned and new allergy bedding provided, before a team of architects installs a ventilation system in the loft. Half of the units will be switched on at the beginning of the study. The other half will be switched on in 12 months time, but only the architects know which units are active. The medical team will compare the asthma, and measures of inflammation in the airways, over that year. It is due for completion in April 2007.

Detailed description

The prevalence of asthma is rising sharply in the UK. The house dust mite is the most common trigger associated with asthma, thriving in the humid microclimate favoured by modern housing. Could this be redressed by investment in improved ventilation in local housing? In a pilot study in North Lanarkshire Council housing stock, we demonstrated that dust mite avoidance, in combination with installation of domestic mechanical heat recovery ventilation (MHRV), could inhibit the re-colonisation of house dust mites by reduction of indoor air humidity. In this second phase, a double blind randomized placebo- controlled trial will test the resultant effect on asthma. It will be complete in November 2006. 140 patients with asthma and house dust mite allergy are being recruited and all will have new bedding, mattress covers and carpets cleaned. All will have MHRV units installed in their home, but only half will be activated, before 12 months of environmental and clinical monitoring. The primary endpoint is morning peak flow rate. Secondary endpoints include symptom scores, spirometry, rates of exacerbations, quality-of-life, and economic evaluations. Demonstration that well ventilated, energy efficient dwellings improve the respiratory health of patients with allergic asthma could be of considerable importance in helping the NHS cope with the commonest chronic disease in Scotland.

Interventions

DEVICEMechanical Heat Recovery Ventilation

De-humidification without loss of heat

Sponsors

Chief Scientist Office of the Scottish Government
CollaboratorOTHER_GOV
North Lanarkshire Council
CollaboratorUNKNOWN
South Lanarkshire Council
CollaboratorUNKNOWN
North Glasgow Primary Care Trust
CollaboratorUNKNOWN
Vent-axia Ltd
CollaboratorUNKNOWN
Scottish Power
CollaboratorUNKNOWN
Energy Action Scotland
CollaboratorUNKNOWN
Communities Scotland
CollaboratorUNKNOWN
University of Glasgow
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
16 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* House dust mite sensitive * FEV1 greater than 50% * Symptomatic asthma or 12% reversibility on spirometry or 15%PEFR lability

Exclusion criteria

* Multi-storey flat

Design outcomes

Primary

MeasureTime frame
morning Peak Flow1 year

Secondary

MeasureTime frame
symptom scores1 year
exacerbation rates1 year
quality of life1 year
spirometry1 year

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026